Identifying sleep disorders in lung cancer patients
Identification and Characterisation of Sleep Disorders in a Population of Patients With Non-small Cell Lung Cancer
This study is trying to find out what sleep problems lung cancer patients have and how these issues affect their daily lives to help improve their treatment.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 100 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | University Hospital, Strasbourg, France Academic / other |
| Locations | 1 site (Strasbourg, Grand Est) |
| Trial ID | NCT06495346 on ClinicalTrials.gov |
What this trial studies
This observational study aims to identify and characterize sleep disorders commonly reported by patients with non-small cell lung cancer. By utilizing self-questionnaires, the study will gather data on how these disorders affect the quality of life of patients. The findings will contribute to creating a decision tree for the diagnosis, referral, and treatment of sleep disorders tailored specifically for this population. Ultimately, the goal is to enhance the management of sleep issues in cancer patients.
Who should consider this trial
Good fit: Ideal candidates for this study are adults aged 18 and over who are being treated for non-small cell lung cancer and can complete questionnaires in French.
Not a fit: Patients with severe mental illness or those under guardianship may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to improved management and treatment of sleep disorders in patients with lung cancer, enhancing their overall quality of life.
How similar studies have performed: While this approach is exploratory, similar studies have shown that addressing sleep disorders in cancer patients can lead to significant improvements in quality of life.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Patient aged 18 and over. * Being monitored and treated for non-small cell lung cancer. * With or without ongoing cancer-specific treatment. With no neurocognitive impairment (MoCA test score ≥26/30). * With a clinically assessed life expectancy of more than 3 months (Royal Marsden Hospital 0-1) and general health (ECOG \<2). * Able to understand the study documents written in French * Able to complete the study questionnaires written in French. * Contactable by telephone throughout the study * Affiliated to a social security scheme or entitled beneficiary * Not opposed to taking part in the study Exclusion Criteria: * Patient refusing to take part in the study * With a mental illness of the psychosis type monitored and treated prior to the study * Patient under guardianship or curatorship * Patient under court protection
Where this trial is running
Strasbourg, Grand Est
- Hus — Strasbourg, Grand Est, France (Recruiting)
Study contacts
- Study coordinator: Laurent Pr CALVEL
- Email: laurent.calvel@chru-strasbourg.fr
- Phone: 03 88 12 83 39
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.